Pharmaceutical nanotechnologies enables novel approaches to drug delivery. Nanoparticles, as drug carriers, impart certain advantages concerning improved efficacy as well as reduced adverse drug reactions. Pharmaceutical nanoparticles allow overcoming pharmacological limitations such as low solubility, rapid biodegradation, low bioavailability, adverse effects, and low permeability through biological barriers. The main challenges in developing PD drug formulations include crossing through the blood-brain barrier and controlled drug release to prevent concentration fluctuations. Pharmaceutical nanoparticles can be prepared from various materials offering variable physicochemical characteristic. Some of the most successful polymeric materials used include gelatin, hyaluronic acid, alginate, chitosan, polylactic-co-glycolic acid (PLGA), polylactide, polyethylene glycol (PEG), and polycaprolactone. For instance, polymeric nanoparticles has been developed based on PEG-polycaprolactone, encapsulating Ginkgolide B, which is believed to act as a neuroprotectant and treat PD. PLGA nanoparticles loaded with L-DOPA have been reported to increase motor function in PD patients. PLGA-PEG nanoparticles were engineered as carriers of coumarin, a potent drug inhibitor of monoamine oxidase B, which could cross the intestinal and brain membranes, allowing the successful transport of coumarin to the brain. Lipid nanoparticles have certain advantages that make them attractive to be used as nanocarriers in PD, mainly their composition based that is physiologically tolerable and their high bioavailability. Liposomes loaded with dopamine hydrochloride and functionalized with transferrin exhibited outstanding stability and improved ability to cross the blood-brain barrier. Semaglutide loaded liposomes demonstrated high stability, bioavailability, passage through the blood-brain barrier, and avoids toxic accumulation due to a half-life of approximately one week. Nalbuphine loaded solid lipid nanoparticles allowed oral/nasal administration and greater dosage control. 220